Abstract
ObjectiveTo evaluate tocilizumab (TCZ) efficacy in patients with refractory Behçet disease (BD).MethodsThis is a multicenter study of 30 patients fulfilling the international criteria for BD and treated with TCZ at different European referral centers. The clinical response was evaluated at 6 months from TCZ initiation.ResultsNinety percent of patients with BD were refractory or intolerant to anti–tumor necrosis factor (anti-TNF) agents. Overall, TCZ was effective in 25 (83%) patients with BD of whom 18 (60%) and 7 (23%) were complete and partial responders, respectively. The complete response was 67%, 60%, and 42% in patients with uveitis (18/30), neurological manifestations (5/30), and mucocutaneous and/or articular (7/30) manifestations, respectively. TCZ had a significant steroid-sparing effect allowing patients to decrease their median daily prednisone dose from 20 (IQR 10-40) mg/day to 9 (IQR 5-13) mg at 6 months (P< 0.001). The number of patients with BD needing concomitant disease-modifying antirheumatic drug therapy fell from 7 (23%) to 4 (13%) at 6 months. Mild to moderate side effects were observed in 6 (20%) patients, and 3 (10%) presented with serious adverse events (pneumonia, intestinal perforation, and septicemia) requiring therapy discontinuation in 2 cases.ConclusionTCZ seems to be an effective alternative to anti-TNF agents in treating BD-related uveitis and neurological manifestations.
Publisher
The Journal of Rheumatology
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference43 articles.
1. Behçet's Disease
2. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis;Davatchi;Expert Rev Clin Immunol,2017
3. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease;Lancet,1990
4. Behçet: the syndrome;Bettiol;Rheumatol,2020
5. Phenotypes in Behçet’s syndrome;Seyahi;Intern Emerg Med,2019
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献